Waters Corporation’s combination with the Biosciences and Diagnostic Solutions businesses of BD (Becton, Dickinson and Company) is now complete.

The finalized transaction, which was previously announced, creates four divisions within Waters:

• Waters Analytical Sciences, formerly Waters Division, excluding Waters Clinical Business
• Waters Biosciences, formerly BD Biosciences
• Waters Advanced Diagnostics, formerly BD Diagnostic Solutions and Waters Clinical Business, and
• Waters Material Sciences, formerly TA Instruments Division.

How Waters Will Restructure Business

Together, Waters said the divisions support development and manufacturing of both large- and small-molecule therapeutics, plus food and environmental testing. Additionally, they advance specialty diagnostics in molecular, microbiology, and multiplex applications.

Waters intends for the combination to establish a global life sciences and diagnostics leader with best-in-class technologies. The company will continue to focus on high-volume testing in regulated applications, as well as expansion into high-growth adjacent markets.

Bringing in BD Biosciences Expertise

“[Combining] with BD’s Biosciences and Diagnostic Solutions businesses marks a pivotal moment,” said Waters President and CEO Udit Batra, PhD.

Batra added it unites “world-class scientific expertise across chemistry, physics, and biology, with rich histories of innovation.”

The ensuing focus, Batra said, is clear.

“Address our customers’ unmet needs, deliver long-term value for our shareholders, and provide solutions that advance global health,” Batra said.

Batra said the companies share category-defining products and a culture of innovation.

“I am confident that together we will accelerate the benefits of pioneering science,” Batra said.

Along with closing this transaction, Waters also named Claire M. Fraser, PhD, to its Board of Directors. She most recently was Director of The Institute for Genome Sciences at the University of Maryland School of Medicine. Fraser founded the Institute in 2007 at the university, where she was a professor of medicine and microbiology and immunology.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.